149 The protocol was four treatments of 50 cc 50% DMSO instilled at two-week intervals with 15-minute retention
Choi J.G., Winn A.N., Skandari M.R., et al
While previous research focused on single or dual-agonist pathways, Retatrutide is a triple-threat compound
Semaglutide is a prescription medication approved by the FDA to help manage type 2 diabetes (Ozempic) and to support long-term weight loss (Wegovy)
However, no direct head-to-head comparisons have been conducted, and the 48-week timeframe in the retatrutide trial is shorter than the 6872 week endpoints used in the semaglutide and tirzepatide phase 3 trials, making direct numerical comparison imprecise
When beginning semaglutide treatment, its normal to have many questions